ARTICLE | Company News
Helsinn, Mundipharma deal
February 16, 2015 8:00 AM UTC
Helsinn granted Mundipharma exclusive, Brazilian commercialization rights to NEPA. The fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg ...